
Photo: STAT
Health
STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
TL;DR
- Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 17, 2026 · Updated 11/17/2026, 12:10:16 PM · Reported with: STAT
Sources (1)
NRI Bytes writes its own articles from the reporting below.
STAT — STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trialUp next · Health
UN report warns endocrine‑disrupting chemicals threaten health and environment
Read next →
More stories

Health
‘I wish he had not returned home’: Father loses three-year-old son in Delhi building collapse, while away at hospital with injured daughter
1h ago

Health
Menopause symptoms aren’t always taken seriously. These female lawmakers plan to change that
1h ago

Health
STAT+: With $173 million, new startup takes aim at sickle cell
1h ago

Health
Early Black Friday deals are here, and I’m tracking the 51+ best ones live: Amazon, PlayStation and more
1h ago
